Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03829514 · ClinicalTrials.gov registry record · Phase 4

Fenofibrate in Type 2 Diabetes

A Phase 4 study, sponsored by Medical University of South Carolina.

Completed
Registry status
Phase 4
Development phase
10
Enrollment target

NCT03829514 is a Phase 4 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 10 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03829514, a Phase 4 study, has completed, sponsored by Medical University of South Carolina.

COMPLETED
Registry status
Phase 4
Development phase
10 participants
Enrollment target

Study Summary

Diabetic complications affecting the eyes, kidneys, and nerves are difficult to arrest once in progress. Recent evidence that fenofibrate confers a robust yet unexpected benefit in diabetic retinopathy offers an important translational research opportunity. The investigator's global proteomic study will provide new clues as to how fenofibrate protects vulnerable tissues, and will spur discovery of targets for new therapeutic interventions.

Interventions

  • DRUG Fenofibrate

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2019-02-04
Est. Completion 2020-03-04
Phase Phase 4

What the Registry Record Tells You About NCT03829514

The ClinicalTrials.gov registry entry for NCT03829514 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Fenofibrate is the first listed.

NCT03829514 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03829514 about?

NCT03829514 is a clinical study titled "Fenofibrate in Type 2 Diabetes". Diabetic complications affecting the eyes, kidneys, and nerves are difficult to arrest once in progress. Recent evidence that fenofibrate confers a robust yet unexpected benefit in diabetic retinopathy offers an important translational research opportunity. The investigator's global proteomic study ...

What is the current status of trial NCT03829514?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2019-02-04. Estimated completion is 2020-03-04.

What interventions are being tested in trial NCT03829514?

The interventions under investigation include: Fenofibrate (DRUG).

Who is sponsoring clinical trial NCT03829514?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.